By MEGGLE Excipients
Subscribe to Supplier
Subscribe to Supplier
MEGGLE bringing DPI insights to PDD 2024 in Dublin
Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE will be a high-profile presence at the upcoming Pulmonary Drug Delivery Workshop in Dublin.
MEGGLE will appear at the conference both as a Gold Sponsor as well as a leading contributor to the scientific agenda, with a presentation on the challenges in optimizing formulations for DPI Dry Powder Inhalation.
DPI challenges
MEGGLE, which is a specialist in lactose-based excipients for DPI applications through its InhaLac® range, will be represented at Trinity College Dublin by its Head of MEGGLE Business Development Inhalation, Dr. Constanze Müller.
Dr. Müller will lead off the Day One Session 3 on ‘DPIs and Particles’ chaired by Prof. Regina Scherließ with her presentation on ‘Challenges associated with DPIs’ (Wednesday April 17, 1400-1425 hrs.).
Her address will review issues such as ensuring optimal particle size distribution (PSD), along with flow and surface characteristics for the powder formulation as well as MEGGLE’s ongoing commitment to address these issues with an expanding range of InhaLac® DPI excipients that are precisely tailored to specific application.
About MEGGLE Wasserburg
Bavarian-based company MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical grade lactose, supplying the pharmaceutical industry with a broad-based and unique lactose product portfolio.
MEGGLEs Business Unit Excipients has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.
A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-technological, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.
The company has introduced several revolutionary products, notably Tablettose®, the world’s first agglomerated pharmaceutical lactose grade for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on powdered cellulose and lactose for outstanding compression and flow properties and RetaLac®, the first direct compressible co-processed excipient using Hypromellose and lactose for sustained release formulations.
To learn more, visit: https://www.meggle-excipients.com/en/home.html
About PDD 2024
Established by Prof. Carsten Ehrhardt in 2013, the Pulmonary Drug Delivery Workshop (PDD) series aims to provide a space for meeting colleagues, discussing research and engaging in new collaborative efforts in the field of inhalation drug delivery.
The conference welcomes graduate students, postdocs and colleagues from academia and industry as well as government agencies.
PDD workshops alternate annually between Dublin and Istanbul to accommodate participants from Western, Central and Eastern Europe as well as from the Middle East and Africa.
The 9th Pulmonary Drug Delivery Workshop, PDD 2024, is a three -day event opening April 17 at Trinity College, Dublin.
The event is organized by the PDD Organisation with further information at: https://www.pulmonarydrugdelivery.org
Resources
Click on MEGGLE Milled lactose for pulmonary and nasal drug delivery for further information.
Click on MEGGLE DPI technologies to view video.
PDD Workshop 2024 Venue: Trinity College Dublin.
Dr. Constanze Müller, Head of MEGGLE Business Development Inhalation.
MEGGLE InhaLac® sieved, milled and micronized lactose-based excipients support a wide range of Dry Powder Inhalation (DPI) applications.
Related Articles
